History
Psoriasis vulgaris (psoriasis) is a chronic skin disease that has affected people's lives since ancient times. In old records, similar skin diseases with “scaling and redness” appeared mixed together under various names, and at the time it was difficult to subdivide and distinguish diseases as we do today. In particular, lesions in which the skin flakes like scales were sometimes confused with other diseases such as leprosy (Hansen's disease), and as a result, social stigma and misunderstanding followed.
As modern dermatology became established, psoriasis began to be defined not as a contagious disease but as a disease in which constitutional predisposition and immune responses are intertwined. Treatment also later developed from “methods of burning the skin or using highly toxic drugs” toward calming inflammation and reducing recurrence. At one time, tar preparations and strong light therapy were representative, and for cases requiring systemic treatment, drugs with immunosuppressive properties were introduced.
Recent research shows a growing trend of understanding psoriasis not as a simple “problem of scaling on the skin surface” but as a systemic inflammatory disease in which immune cells and skin cells stimulate each other and an inflammatory loop is sustained. This shift in perspective has also affected treatment goals. Awareness has widened that it is important to manage not only reducing skin lesions but also quality of life and the risk of coexisting conditions together.
Causes
The cause of psoriasis vulgaris cannot be neatly summarized as one thing. The core is a structure in which “when several environmental factors overlap in a person with a genetic predisposition, the immune response is switched on excessively and the skin reacts hypersensitively to that stimulus.” Therefore, psoriasis can develop in anyone, but even with the same stimulus, it may not develop in some people while it repeatedly worsens in others.
Frequently mentioned aggravating factors include seasonal change (especially winter), physical damage to or irritation of the skin, infection, stress, and some medications. The phenomenon in which new psoriasis lesions develop where the skin has been scratched or wounded is called the Koebner phenomenon, and it shows that skin injury can act like a “switch.” Infection can be an especially important trigger in guttate psoriasis, in which small rashes spread rapidly.
Medications can also have an effect. For example, beta-blockers, nonsteroidal anti-inflammatory drugs (NSAIDs), lithium, and others may be associated with worsening in some people, and it is also known that psoriasis can worsen severely when steroids (especially systemic steroids) are stopped abruptly. However, this does not mean that “taking a particular drug will always cause psoriasis”; the individual's predisposition and circumstances act together.
Recent research also emphasizes that lifestyle factors such as smoking, obesity, and heavy drinking can raise the inflammatory state and affect symptoms. So the practical conclusion about causes is twofold. First, it is difficult to change constitutional predisposition, but second, reducing aggravating factors leaves room to lower the intensity and frequency of recurrence.
Genetic Epidemiology
Psoriasis vulgaris is not a typical “single-gene disease,” but it tends to cluster relatively often within families. A family history is not uncommon, and twin studies also clearly show a genetic influence. Rather than “genes directly determining the disease,” it is realistic to understand that they form a constitutional background in which the immune response readily overheats.
Genetically, gene variants related to immune function are repeatedly mentioned. In particular, many variants are associated with the signaling systems that regulate the direction of the immune response, and the risk can increase the more variants overlap. For this reason, it is natural to view psoriasis as a combination of “genetics + environment.” Its features may also look different depending on the age of onset. Cases that begin at a young age tend to be relatively associated with family history, while in cases that begin after middle age, family history is sometimes less clear.
Recent research has refined the explanation that in people with a genetic predisposition, certain immune pathways are activated more easily, and as a result the keratinocytes of the skin repeat hyperproliferation and inflammatory responses. However, there is not yet a standard strategy in everyday practice of “predicting and preventing in advance” with genetic testing alone. Therefore, the key message of genetic epidemiology can be summarized as follows: because the risk may be higher if there is a family history, early recognition and management of aggravating factors become more important.
General Epidemiology
Psoriasis vulgaris is a chronic disease that is relatively common worldwide. Prevalence varies greatly by region and race, and may also be associated with latitude, climate, and lifestyle. Overall, it is known to be reported more commonly in populations of European descent and relatively less commonly in East Asia.
Onset is possible at any age, but it commonly first appears in adulthood, and it is not uncommon for it to begin in adolescence or young adulthood. The frequency in men and women is known to be similar. The typical course is a long-term one that repeatedly “gets better and then worse.”
Psoriasis vulgaris may not end as a problem of the skin alone. In some people, psoriatic arthritis may accompany it, and associations with cardiovascular disease, metabolic disease, depression, and others have been noted in connection with systemic inflammation. These coexisting conditions tend to become more important when psoriasis is severe or long-standing, so overall health should be looked at together, not just the area of skin lesions.
Recent research repeatedly emphasizes that detecting and managing coexisting conditions early in patients with psoriasis is important for long-term prognosis. Therefore, to summarize general epidemiology in practical terms, it is helpful to remember that “it is a common chronic disease, and although lesions visible on the skin are the starting point, it can affect both daily inconvenience and overall health.”
Pathogenesis
The pathogenesis of psoriasis vulgaris can start with one sentence: “the immune system overstimulates the skin, and the skin responds to that stimulus with excessive proliferation.” The skin is originally a barrier that blocks external stimuli, but in psoriasis this barrier enters a state of “overreaction,” creating a situation in which the inflammation does not switch off.
Simplified, the flow is as follows. When stimuli such as skin injury, infection, medication, or stress occur, immune cells in the skin (e.g., dendritic cells) are activated and inflammatory signals increase. Then T cells become more activated and gather in the skin, producing more of the signaling substances (cytokines) that sustain inflammation. Typically, pathways such as tumor necrosis factor alpha (TNF-α), interleukin 17 (IL-17), and interleukin 23 (IL-23) are repeatedly emphasized.
Keratinocytes that receive these signals divide much faster than normal, and their maturation process is disrupted. As a result, the skin thickens, silvery-white scales pile up, and a “psoriatic plaque” with a red base is formed. In fact, in psoriatic lesions the turnover cycle of skin cells is explained as becoming much shorter than normal (roughly one month), speeding up to a matter of days.
Recent research discusses concepts such as skin barrier proteins, microbes (the skin or gut flora), inflammation and vascular changes, and immune memory together, expanding the explanation of why some people relapse easily even with small stimuli and why some respond better to certain treatments. The key takeaway for the general public is that psoriasis does not arise “because the skin was not washed well enough,” but is a constitutional inflammatory response in which immunity and the skin are intertwined.
Symptoms
The symptoms of psoriasis vulgaris center on visible skin changes, but in everyday life the hardest parts are often itching, stinging, pain, and the fatigue caused by repeated relapses. A typical lesion consists of white, silvery-looking scales piled up layer upon layer on a base that is red or pink, or closer to purplish in people with darker skin. When these lesions become wide and thick, the skin can crack and bleed or the stinging can become severe.
The locations where lesions tend to occur are also part of the symptoms. They tend to appear on frequently rubbed areas such as the elbows and knees, as well as the scalp, shins, around the navel, and the lower back (lumbosacral region). Scalp psoriasis looks like dandruff, so it is easily misunderstood as “caused by an unclean scalp,” which can increase stress.
When the nails are involved, pitting, in which the nails become uneven with small dents, discoloration, lifting, and crumbling can occur, and the inconvenience can increase in terms of manual work and appearance. In addition, some people have joint pain or morning stiffness, in which case psoriatic arthritis should be suspected. Fingers or toes that swell “like sausages” and persistent low back or buttock pain are also clues.
Recent research emphasizes that “sensations” such as itching and pain are not mere secondary symptoms but key elements that reflect disease activity and greatly determine quality of life. So when setting treatment goals, we look not only at “whether the lesion area has decreased” but also at “how much itching and pain, sleep, and difficulties in social relationships have improved.”
Signs
Signs refer to objective findings observed by the medical team. The representative sign of psoriasis vulgaris is a red plaque (psoriatic plaque) with relatively well-defined borders, covered with overlapping silvery-white scale (scale-like flakes). When touched, the lesion feels raised, and a difference in height from the surrounding skin can be felt.
The Auspitz sign is the finding that small, pinpoint bleeding may be seen when the scale is gently removed; it does not always appear in every patient, but when typical, it helps with diagnosis. The Koebner phenomenon is the development of new psoriasis lesions at sites of irritation such as scratches, surgical scars, tattoos, and burns, and it is an important clue when a patient says, “I got a wound and it started right there.”
Nail signs are also important. Pitting of the nails, thickening of the keratin under the nails, and lifting of the nails can be confused with a simple fungal infection, but looking at the distribution and accompanying skin lesions together helps tell them apart. On the scalp, relatively well-defined red plaques and thick scales are seen, yet the hair itself often does not fall out.
Another important sign is “distribution.” Appearing symmetrically on the outer sides (extensor surfaces) of the elbows and knees, or recurring on the lower back and scalp, strongly suggests psoriasis clinically. Conversely, an eczema-like pattern with oozing or poorly defined borders, a fungal infection pattern spreading in rings, or a seborrheic dermatitis pattern centered on the face should be considered in the differential diagnosis.
Screening
In psoriasis, “screening” usually does not mean sorting people out all at once with a blood test, but is closer to a process of quickly checking the risk factors and coexisting conditions needed for diagnosis and treatment planning. First, the most important thing is the medical history. The patient is asked when it started, whether it recurs, whether there is a family history, whether it worsens in winter, whether it worsens after stress or infection, and whether any medication was recently started. Symptoms outside the skin, such as joint pain, morning stiffness, swelling of the fingers and toes, and symptoms of eye inflammation, are also checked.
Next, skin irritants are checked. Excessive cleansing, hot baths, frequent scrubbing, scratching habits, and dry skin can worsen the barrier and intensify symptoms. In terms of lifestyle, items such as smoking, heavy drinking, weight gain, and lack of sleep are important.
Screening for severity is also needed. It is checked how much of the body the skin lesions cover, whether there are sites such as the scalp, hands and feet, or genitals that “have a large impact on life even if the area is small,” and how severe the itching and pain are. In clinical practice, tools such as body surface area (BSA), the Psoriasis Area and Severity Index (PASI), and the Dermatology Life Quality Index (DLQI) are sometimes used to determine the treatment stage.
Recent research shows a trend of recommending that basic health indicators such as blood pressure, blood sugar, lipids, and body weight also be checked, considering the risk of coexisting conditions. Therefore, the core of screening can be summarized as “not looking only at the skin, but checking systemic risk and aggravating factors together to decide the direction of treatment.”
Diagnosis
The diagnosis of psoriasis vulgaris is mostly a “clinical diagnosis.” In other words, it is often diagnosed by looking at the shape and distribution of the lesions and their course. When characteristic red plaques and silvery-white scales, a distribution such as the elbows, knees, scalp, and lumbosacral region, a pattern of relapse and worsening, family history, and triggering factors are combined, the diagnosis becomes relatively clear.
Nevertheless, because many diseases look similar, differential diagnosis is important. Eczema has poorly defined borders and may be accompanied by oozing, and fungal infections may have more distinct edges or spread in rings. Seborrheic dermatitis may be characterized by greasy scales centered on the scalp and face. Rarely, diseases such as cutaneous T-cell lymphoma can look like psoriasis, so caution is needed when the course is atypical or the response to treatment is unusual.
When the diagnosis is uncertain, a skin biopsy is considered. Under the microscope, relatively typical histological findings of psoriasis can be observed, supporting the diagnosis. In addition, when nail lesions are predominant, fungal testing or culture may also be considered to rule out fungal infection.
If there are accompanying joint symptoms, evaluation for psoriatic arthritis is needed. This may include evaluation from a rheumatologic perspective beyond the dermatologic diagnosis, and imaging tests or checks of inflammatory markers may be added if necessary. It is best to understand diagnosis not as simply “putting a name to the disease,” but as a process of identifying the extent of the disease and accompanying problems together to establish a treatment strategy.
Treatment
Treatment of psoriasis vulgaris proceeds “step by step according to the severity of the disease.” Rather than speaking of a cure, the goal is often control and remission. In mild cases, topical medications can bring sufficient improvement. Typically, topical corticosteroids and vitamin D analogs are widely used, and using the two together often gives a good balance of efficacy and safety. Emollients that keep the skin moist are also closer to a basic treatment than an “adjunct.”
If the disease is moderate or worse or difficult to control with topical medications alone, phototherapy can be considered. In particular, narrowband ultraviolet B (NB-UVB) therapy is commonly used. While its treatment effect is good, there is the burden of regular hospital visits, and the risk of long-term ultraviolet exposure must be considered.
In more severe cases, systemic treatment is needed. Traditionally, methotrexate (MTX), cyclosporine, and the retinoid class have been used. These drugs can be effective, but they require regular monitoring of liver function, kidney function, blood tests, and so on, and caution is needed in situations such as planning a pregnancy.
Biologics (biological therapy) are a treatment approach that targets specific inflammatory pathways and can be of great help in patients with severe psoriasis or accompanying arthritis. For example, drugs targeting pathways such as TNF-α, IL-17, and IL-23 are known. Recent research emphasizes that targeted therapy can play an important role not only for skin lesions but also in improving quality of life, but infection risk, cost, long-term safety, and individual differences in response must be considered together. The most important principle in treatment is that goals must be set differently for each patient.
Prognosis
The prognosis of psoriasis vulgaris varies greatly between individuals. In some people, small lesions appear intermittently and are well controlled with topical medications, while in others the disease may spread widely or worsen repeatedly and require systemic treatment. It typically shows a long-term course of repeated improvement and worsening, and some people experience a pattern of worsening in winter and improving in summer.
With good treatment, it is possible to greatly reduce skin lesions or make them almost invisible, but relapse is common when treatment is stopped, so the perspective of “a disease to be managed” is important. In particular, involvement of sensitive areas such as the hands and feet, scalp, and genitals can greatly reduce quality of life regardless of the size of the lesions, so it is important in assessing prognosis.
Another pillar that determines prognosis is coexisting conditions. If joint symptoms accompany the disease, joint damage can accumulate, so early detection is important, and because metabolic and cardiovascular risks associated with systemic inflammation may also be present, lifestyle management affects long-term prognosis. Psychological burden is also part of the prognosis. Self-consciousness due to changes in appearance, difficulties in social relationships, and depressed mood can affect treatment adherence and relapse.
Recent research shows growing interest in markers that predict treatment response and in personalized treatment, but for now a process of working together to find “which treatment suits each person best” is still necessary. Therefore, prognosis is not determined simply by the size of the skin lesions, and should be assessed by considering coexisting conditions, lifestyle factors, and the sustainability of treatment together.
Prevention
Because a genetic predisposition is involved in psoriasis vulgaris, “complete prevention” is not always possible. However, there are clearly preventive strategies that reduce worsening and relapse. The most basic is protecting the skin barrier. Because dryness readily worsens psoriasis, gentle cleansing and sufficient moisturizing are important. It is best to avoid habits such as washing for a long time with hot water or using harsh scrubs.
Preventing skin injury is also key. Scratching habits, repeated friction, wounds, and burns can create new lesions through the Koebner phenomenon, so when itching is severe, the itching should first be reduced with appropriate treatment. The risk of relapse is also considered when planning tattoos or unnecessary skin procedures.
Managing infections and stress is also practical prevention. Some people worsen rapidly after situations in which a streptococcal infection is suspected, such as a sore throat or tonsillitis, so knowing your own pattern and responding early is helpful. Stress is hard to dismiss as merely “a matter of the mind,” and because it can actually be a trigger that worsens symptoms, basic routines such as sleep, rest, and exercise are important.
Do not stop or change medications on your own, and consult the medical team when starting a new medication that may be associated with worsening psoriasis. In particular, using systemic steroids on your own or stopping them abruptly can be dangerous.
Recent research repeatedly mentions that lifestyle habits such as weight management, quitting smoking, and moderating alcohol intake can lower systemic inflammation and have a positive effect on treatment response. Ultimately, the gist of prevention is “protecting the skin, reducing triggers, and managing overall health together.”